China Pharma Holdings Reports on Shareholder Votes

TL;DR

China Pharma Holdings filed an 8-K about shareholder votes, no major financial news.

AI Summary

China Pharma Holdings, Inc. filed an 8-K on December 26, 2024, reporting on matters submitted to a vote of security holders as of December 22, 2024. The filing details the company's corporate actions and governance, with no specific financial transactions or significant events mentioned in the provided text.

Why It Matters

This filing indicates that the company is engaging in corporate governance activities, which can impact shareholder rights and the company's strategic direction.

Risk Assessment

Risk Level: low — The filing is procedural and does not disclose any new financial risks or significant operational changes.

Key Players & Entities

• CHINA PHARMA HOLDINGS, INC. (company) — Registrant
• December 22, 2024 (date) — Earliest event reported
• December 26, 2024 (date) — Filing date

FAQ

Key Financial Figures

• $0.001 — every holder of common stock, par value $0.001 per share, of the Company, shall receiv

Filing Documents

• ea022580301-8k_chinapharma.htm (8-K) — 38KB
• 0001213900-24-112658.txt ( ) — 210KB
• cphi-20241222.xsd (EX-101.SCH) — 3KB
• cphi-20241222_lab.xml (EX-101.LAB) — 33KB
• cphi-20241222_pre.xml (EX-101.PRE) — 22KB
• ea022580301-8k_chinapharma_htm.xml (XML) — 4KB

07. Submission of Matters to a Vote

Item 5.07. Submission of Matters to a Vote of Security Holders. On December 22, 2024, China Pharma Holdings, Inc. (the " Company ") held its annual stockholders' meeting for the fiscal year ended December 31, 2023 (the " Annual Meeting "). Holders of 9,688,133 shares of the Company's common stock were present in person or by proxy at the Annual Meeting, representing approximately 52% of the total outstanding shares of common stock and therefore constituting a quorum of more than one-third of the shares outstanding and entitled to vote at the Annual Meeting as of the record date of November 1, 2024. The final voting results for the matters submitted to a vote of stockholders at the meeting are as follows. 1. A proposal to elect five director nominees to our Board of Directors: Independent Director's Name Votes For Votes Withheld Zhilin Li 9,369,099 19,508 Heung Mei Tsui 9,369,099 19,508 Gene Michael Bennett 9,368,708 19,899 Yingwen Zhang 9,368,681 19,926 Baowen Dong 9,368,705 19,902 Pursuant to the foregoing votes, Zhilin Li and Heung Mei Tsui were elected to serve as our non-independent directors until the date of the annual shareholders meeting in three years and until their respective successors are duly elected and qualified. Gene Michael Bennett, Yingwen Zhang and Baowen Dong were elected to serve as our independent directors until the next annual meeting and until their successors are elected and qualified. 2. A proposal to adopt the Amendment No.2 to the Company's Amended and Restated 2010 Long-Term Incentive Plan: Votes For Votes Against Abstentions 9,365,051 23,322 234 Pursuant to the foregoing votes, the Amendment No.2 to the Company's Amended and Restated 2010 Long-Term Incentive Plan was approved and adopted. 3. A proposal to amend the Company's Articles of Incorporation to effect a reverse stock split, as needed at a ratio between 1:10 and 1:20, such that every holder of common stock, par value

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: December 26, 2024 CHINA PHARMA HOLDINGS, INC. By: /s/ Zhilin Li Name: Zhilin Li Title: President and Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR